have previously shown that a-mercaptopropionylglycine (a-MPG) and sodium dipropylacetate (DPA) facilitate immunity as well as host-mediated anti tumor activity. In this study, we found that a compound related to a-MPG and DPA,
It is well known that tumor specific antigen exists on the tumor cell membrane, and a tumor bearing host immunologically resists the tumor. Currently, some immunopoten tiators are applied to the treatment of cancers, but since their therapeutic effect is not sufficient, they cannot induce enough tumor immunity to lead to an involution of cancers. Therefore, these drugs are seldom used as a single drug, and they are usually combined with cytocidal carcino-static agents, radio therapy and/or operation (1 ). Nevertheless, they are expected to be a powerful means to completely eliminate the small volume of tumor cells which may remain after some treatments and to prevent recurrence. On the other hand, effects of cytocidal carcino static agents are more definite, but it is usually impossible to continue the treatment until tumor cells are completely eliminated because of their side effects, especially strong immune suppression. Further, this immune suppression is disadvantageous to tumor immunity. Authors have demonstrated that a-mercaptopropionylglycine (a-MPG) and sodium dipropylacetate (DPA) have im munostimulating effects (2), antagonize cyclophosphamide and azathioprine (3), and show a host-mediated carcino-static effect in the syngeneic system of C57BL/6 mice transplanted with E. L.4 lymphosarcoma (E.L.4) (4). Based on these evidences, authors have tried to combine a-MPG, DPA or a compound related to these with various cytocidal carcino-statics, with the intention of developing drugs which have less im munosuppressive effect, and furthermore, facilitate tumor immunity. In this study, an examination was made on the anti-tumor effect of a compound related to a-MPG and DPA, (2-n-propyl-n-pentanoyl) glycine (KN 539). Furthermore, anti-tumor effects and H. MORI ET AL. 
Materials and Methods
Drugs: KN-539, KN-826 and KN-827 were synthesized at the Kissei Pharmaceutical Industry Co., Ltd. KN-826 and KN-827 were dissolved in sterilized physiological saline solution or distilled water with NaHC03 on an equimolar basis of the compounds; and KN-539, N1-(2-tetrahydrofuryl)-5-FU (FT 207) (Taiho Pharmaceutical Industry Co., Ltd.) and 5-FU (Nakarai Chemicals) were dissolved in sterilized physiological saline solution or distilled water immediately before use. The concentration was adjusted so that the dose of each compound was 0.2 ml/ animal, and the solutions were filtrated and sterilized by using 0.45 jcm Millipore filters.
Animals:
Four and 10-week old male C57BL/6 mice and 8-week old male dd strain mice were used in the experiments on transplantation of E.L.4 and on antibody production, respectively. Since experiments of a-MPG and DPA in 4-week old C57BL/6 male mice transplanted with E.L.4 had shown the strongest host-mediated carcino-static effect, mice of this age and sex were mainly used in this study for determination of the carcino-static effect. Animals were fed in a temperature humidity controlled room Tumor size (cm3)= 4 3 n X long diameter ( -? -) X short diameter )2 to the method of Cunningham and Szenberg (5). In addition, the number of the spleen cells, blood leukocyte count and serum hemolysin titer were also determined at the same time. The number of spleen cells and blood leukocyte count were determined using a Coulter Counter (Model Z, Coulter Electro nics Inc.) after Zap-oglobin II (Coulter Electronics Inc.) was added into the cell suspension diluted with Isoton (Coulter Electronics Inc.) for lysing the red cells. The hemolysin titer was determined according to the microtiter method in which serial two fold dilutions of the serum (0.05 ml) were prepared, and the maximum dilution number for complete hemolysis (107 SRBC) was regarded as the hemolysin titer.
All data were statistically analyzed by Table 1 . The tumor growth was dose-dependently inhibited on days 10 and 12, and the inhibition was also significant on day 15 in each dosage group. Though the tumor growth in the 5 mg/kg group was inhibited significantly, the survival time of this group was not prolonged dis tinguishably, so that mean survival times in the control group and in 5 mg/kg group were 19 and 20.3 days, respectively. The prolon gation was observed in 10 and 20 mg/kg groups which had survival times of 20.6 and 21.6 days, respectively, but they were not conspicuous as compared with the control group. Therefore, the tumor growth was regarded as the index for judging the anti cancer effect in the following experiments. Since decrease in body weight was observed even in the control group because the 4-week old mice were too young, 10-week old male mice were on day 10, and inhibition by KN-827 was significant on day 12 in doses of 0.2 and 0.6 mM/kg. FT-207 significantly inhibited in a dose-dependent fashion on days 10 and 12, and in the 0.6 mM/kg group, the inhibition continued on day 15. A significant inhibition by 5-FU was also obtained at each obser vation time.
Changes in the body weight of mice treated with these drugs are shown in Table 5 .
Changes in the body weight were expressed as percentage of increment to the initial weight before the drug treatment. The body weight was not remarkably changed by KN-826 and KN-827 in any dosage group. In contrast, the body weight in the FT-207 group was decreased in a dose-dependent manner on day 10, and the decrease was especially remarkable in the 0.4 and 0.6 mM/ kg groups. The body weight in the 0.2 mM/ kg group of 5-FU was decreased more than that in the 0. The results on the blood leukocyte count are shown in Table 6 . Treatment with KN-827 showed an increase in the blood leukocyte count on days 3 and 5, and the increase was significant on day 5. Although a slight increase of blood leukocytes was observed by the treatment with FT-207 at doses of 0.2 and 0.4 mM/kg on day 5 and at 0.6 mM/ kg on day 7, there was no difference from the control in others. Significant and remarkable decrease in the blood leukocyte count was observed on day 5 and 7, respectively, in the 0.2 mM/kg group of 5-FU.
The results on the number of spleen cells are shown in Fig. 3 . Treatment with KN-827 in a dose of 0.6 mM/kg and 0.2 mM/kg showed a tendency to increase the number of spleen cells on day 3 and on day 5, respectively. The compound in doses of 0.4 and 0.6 mM/kg also caused an increase on The assay was carried out 3, 5 and 7 days after the immunization.
Each column re presents the mean±S.E. Each group on day 3 included 4 animals, and the others on days 5 and 7 included 5 animals. *, t: Statistical significance from the control at P<0.05 and P<0.01, respectively. Each group on day 3 included 4 animals, and the others on days 5 and 7 included 5 animals. ", t: Statistical significance from the control at P`0.05 and P<0.01, respectively.
day 7, and it was significant in the former dose. Treatment with FT-207 showed a tendency to decrease the number of spleen cells in the 0.4 and 0.6 mM/kg groups on days 3 and 5 and also showed a similar tendency in the later dose group on day 7. 5-FU also showed a tendency to decrease it in the 0.1 mM/kg group on days 3 and 5, and a significant decrease was found in the 0.2 mM/kg group on the same days. The results on the HPFC production are shown in Fig. 4 . The number of H PFC per spleen was dose-dependently increased by KN-827 treatment on day 3, and it increased also in the 0.2 and 0.6 mM/kg groups on day 5, which was the day of maximum HPFC production. On the other hand, treatment with FT-207 in doses of 0.2 and 0.6 mM/kg decreased the number of HPFC per spleen on day 5. 5-FU in doses of 0.1 and 0.2 mM/kg decreased the number of H PFC per spleen on both days 3 and 5, and the decrease was significant in the 0.2 mM/kg group on day 5. The result on the number of the H PFC per 106 spleen cells was similar to that on the number of HPFC per spleen (Data are not shown).
The results on the hemolysin titer are shown in Table 7 . Treatment with KN-827 in a dose of 0.2 mM/kg showed a tendency to increase the hemolysin titer on day 3, but a significant decrease was found in the 0.4 mM/kg group on day 5, which was the day of maximum response. There was no sig nificant difference from the control in the others. Treatment with FT-207 in doses of 0.4 and 0.6 mM/kg resulted in a significant decrease in the hemolysin titer on day 5, and the effect was remarkable in the higher dose. gesting less toxicity of KN-827 as compared with FT-207. Therefore, a study was con ducted in order to determine the effect of these compounds on the immune response. Though it is known that FT-207 causesless injuries of the bone marrow (7), a large dose and/or long-term treatment with FT-207 resulted in a decrease in the blood leukocyte count (8). In this experiment, leukocyte count in the blood was not influenced by FT-207, but was decreased by 5-FU in a dose of 0.2 mM/kg. On the other hand, it was increased remarkably by KN-827. Further, the number of spleen cells was obviously decreased by FT-207 and 5-FU, but not decreased by KN-827. H PFC-production on days 3 and 5 tended to be facilitated by KN-827, while it was obviously inhibited by FT-207 and 5-FU. Hemolysin-production in the blood was inhibited remarkably by FT-207 and 5-FU, but was slightly influenced by KN-827. In these results, obvious inhibition of the immune response was observed with FT-207 and 5-FU, while, on the contrary, a tendency to stimulate the response appeared with KN-827 treatment in doses which had been proved to induce anti-tumor activity. FT-207 is a masked compound, and it is considered that this compound is changed to 5-FU in the liver, and the free 5-FU con tributes to the anti-cancer effect (9, 10) . Though the mechanism of the anti-cancer effect of KN-827 has not been clarified, it is presumed that if this compound has a mode of action similar to FT-207, (2-propyl-n pentanoyl)glycine in the side chain or its metabolites antagonizes the immuno suppressive activity of 5-FU. However, as KN-827 rather facilitated the immunity leading to an increase in the blood leukocytes, there is a possibility that KN-827 produces the anti-tumor effect through a mechanism essentially different from that of FT-207. We are now investigating the mechanism(s) of the anti-tumor effect in KN-827. 
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